



Investor fact sheet

June 2010

Futura Medical plc

Surrey Technology Centre
40 Occam Road
The Surrey Research Park
Guildford, Surrey, GU2 7YG

Tel: 01483 685670
info@futuramedical.com
www.futuramedical.com

Management

Chairman Dr Bill Potter
Chief Executive James Barder
Product Development Director
David Davies
Finance Director Derek Martin

Share statistics (as at close 29 June 2010)

Share price (p): 41.00p
Shares in issue (m): 67.48
Market cap (£m): 27.67
Year end: 31 December

Sector: Pharmaceuticals

Activities: Innovative products
for consumer health
Broker/NOMAD: Nomura Code
Securities Limited

Top 5 shareholders - April 2010

RA Lamb	7.7%
WT Lamb Investments	6.4%
Medinvest	5.9%
CJ Crabtree	4.2%
Gartmore	4.8%

Company overview

Futura Medical plc is a pharmaceutical group that develops innovative products for the consumer healthcare market. Futura's shares trade on AIM. We have five products in our development pipeline for sexual healthcare and pain relief management: CSD500, PET500, MED2002, TPR100 and RAD100 (see next page). We are evaluating further product opportunities for our Dermasys® technology.

Strategy

- **Return on Investment:** we focus on consumer healthcare products that offer the potential for a significant return on the costs of development.
- **Product Profile:** We only incorporate existing chemical entities into our products which gives our development activities a lower risk profile.
- **Over The Counter ("OTC"):** our aim is to produce safe and effective OTC products made available to consumers on a general retail basis or through chemists without the need for a doctor's prescription.
- **Strong Intellectual Property:** the products are underpinned by our developing and retaining valuable intellectual property including know-how, patents and trademarks to protect their commercial position.
- **Licensing:** we aim to out-license our products during their development to established pharmaceutical and healthcare groups which offer the best potential commercial opportunities.

Partnerships

Futura has signed a global distribution agreement with the world's largest branded condom manufacturer and distributor, **SSL International plc** (makers of the Durex® condom range) for CSD500 for the lifetime of the patents.



Futura also signed a global development and licensing agreement with SSL International plc for MED2002.

In June 2010, we signed an agreement with GlaxoSmithKline plc for the development of TPR100, our topically applied product for pain relief. In addition, we are in non-exclusive discussions for the distribution rights to our product for premature ejaculation PET500.

Key financial data

	Year ended 31 Dec 09 (£'000)	Year ended 31 Dec 08 (£'000)	Year ended 31 Dec 07 (£'000)
Income	80	224	111
R&D	(810)	(1,391)	(1,508)
Other administrative costs	(796)	(1,008)	(1,227)
Operating loss	(1,526)	(2,175)	(2,624)
Finance income	14	97	161
Tax credit receivable	119	143	209
Loss after tax	(1,393)	(1,935)	(2,254)
Net cash	1,789	782	2,638

Recent news flow

- 30 June 10: TPR100 Agreement with GSK
- 12 May 10: Results of AGM and AGM Statement
- 01 April 10: CSD500 Dossier Submitted for Approval
- 30 March 10: Notice of AGM
- 02 March 10: Preliminary Results for the year to 31 Dec. 09
- 02 February 10: CSD500 Update
- 01 February 10: Notification of Preliminary Results

6 month share price performance



Product pipeline

Sexual healthcare

Concept → Commercialisation

CSD500

Next milestone: Granting of the CE mark

CSD500 is a condom that incorporates an erectogenic compound which comes into contact with the penis on application of the condom. This is aimed at helping healthy men maintain a firmer erection during intercourse whilst wearing a condom.

PET500

EU

Next milestones: Out-licensing deal - Pivotal clinical trial

US

Next milestone: Out-licensing deal

PET500 is a spray for men with premature ejaculation. It contains anaesthetic compounds which reduce sensitivity to help prolong sexual intercourse.

Delivered by 

MED2002

Next milestone: Pivotal clinical trial

MED2002 is a topical gel applied directly to the penis for the treatment of male erectile dysfunction. It is expected to be the first OTC treatment for men with erectile dysfunction.

Delivered by 

Pain relief management

Concept → Commercialisation

TPR100

EU/ROW

Next milestone: Clinical trial programme

US

Next milestone: Out-licensing deal

TPR100 is a product for the provision of topical pain relief. Early clinical work has shown superiority in terms of skin penetration of the active compound compared with the market-leading product.

Delivered by 

RAD100

Next milestone: Early stage clinical trial

RAD100 will be a product which aims to provide rapid local anaesthesia prior to injection, vaccination or cannulation.

Delivered by 

Buchanan Communications

Mark Court

markc@buchanan.uk.com

Telephone: +44 (0)20 7466 5000

Futura Medical plc

James Barder, Chief Executive

james.barder@futura-medical.com

Telephone: +44 (0)1483 685 670

